At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01177 SINO BIOPHARM
Closed 12-05 16:09:08
6.840
-0.040
-0.58%
High6.880Low6.680Vol48.89M
Open6.880D1 Closing6.880Amplitude2.91%
Mkt Cap128.33BTradable Cap128.33BTotal Shares18.76B
T/O332.78MT/O Rate0.26%Tradable Shares18.76B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
SINO BIOPHARM (01177) Receives NMPA and FDA Approval for Clinical Trial of TQF3250, an "Oral Biased GLP-1 Receptor Agonist"
Stock News  ·  12-04 17:30
SINO BIOPHARM (01177) Receives NMPA and FDA Approval for Clinical Trial of TQF3250, an "Oral Biased GLP-1 Receptor Agonist"
BRIEF-Sino Biopharmaceutical Says Tqf3250 Clinical Trial Approved By NMPA And FDA
Reuters  ·  12-04 17:26
BRIEF-Sino Biopharmaceutical Says Tqf3250 Clinical Trial Approved By NMPA And FDA
Sino Biopharmaceutical Wins NMPA and FDA Approval to Trial Oral GLP-1 Drug for Weight Loss
Reuters  ·  12-04 17:25
Sino Biopharmaceutical Wins NMPA and FDA Approval to Trial Oral GLP-1 Drug for Weight Loss
Sino Biopharmaceutical - Tqf3250 Trial Approved by Nmpa and FDA
THOMSON REUTERS  ·  12-04 17:25
Sino Biopharmaceutical - Tqf3250 Trial Approved by Nmpa and FDA
Sino Biopharmaceutical Stock Advances 1.9% in Hong Kong, Outperforms Competitors
Dow Jones  ·  12-04 16:30
Sino Biopharmaceutical Stock Advances 1.9% in Hong Kong, Outperforms Competitors
HKEX Announcement Highlights | Innoscience and ON Semiconductor Sign Strategic Agreement to Accelerate GaN Industry Ecosystem Development
Stock News  ·  12-03 23:10
HKEX Announcement Highlights | Innoscience and ON Semiconductor Sign Strategic Agreement to Accelerate GaN Industry Ecosystem Development
10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled
Stock News  ·  12-03 19:38
10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled
SINO BIOPHARM (01177): Rotigotine Patch Approved for Market Launch
Stock News  ·  12-03 16:42
SINO BIOPHARM (01177): Rotigotine Patch Approved for Market Launch
BRIEF-Sino Biopharmaceutical Says Rotigotine Patch Approved For Marketing In China
Reuters  ·  12-03 16:32
BRIEF-Sino Biopharmaceutical Says Rotigotine Patch Approved For Marketing In China
SINO BIOPHARM (01177) Completes First Patient Enrollment in Phase I Clinical Trial for Innovative Drug TRD208 in China
Stock News  ·  12-01
SINO BIOPHARM (01177) Completes First Patient Enrollment in Phase I Clinical Trial for Innovative Drug TRD208 in China
Sino Biopharmaceutical Enrolls First Patient in Phase I Trial of Non-Opioid Analgesic TRD208
Reuters  ·  12-01
Sino Biopharmaceutical Enrolls First Patient in Phase I Trial of Non-Opioid Analgesic TRD208
Sino Biopharmaceutical Stock Slides 1.8% in Hong Kong, Underperforms Competitors
Dow Jones  ·  12-01
Sino Biopharmaceutical Stock Slides 1.8% in Hong Kong, Underperforms Competitors
Sino Biopharm (01177) Announces November 2025 Monthly Return with No Changes in Share Capital
Bulletin Express  ·  12-01
Sino Biopharm (01177) Announces November 2025 Monthly Return with No Changes in Share Capital
SINO BIOPHARM (01177) Surges Over 4% as Subsidiary's HER2 Bispecific ADC Achieves Breakthrough in Breast Cancer Neoadjuvant Therapy
Stock News  ·  11-26
SINO BIOPHARM (01177) Surges Over 4% as Subsidiary's HER2 Bispecific ADC Achieves Breakthrough in Breast Cancer Neoadjuvant Therapy
China Approves LM-350 Clinical Trials; Could Be a Game Changer for Sino Biopharm (SEHK:1177)
Simply Wall St.  ·  11-26
China Approves LM-350 Clinical Trials; Could Be a Game Changer for Sino Biopharm (SEHK:1177)
Sino Biopharmaceutical Stock Advances 1.5% in Hong Kong
Dow Jones  ·  11-25
Sino Biopharmaceutical Stock Advances 1.5% in Hong Kong
Sino Biopharmaceutical Limited's (HKG:1177) largest shareholder, CEO S. Y. Tse sees holdings value fall by 7.4% following recent drop
Simply Wall St.  ·  11-24
Sino Biopharmaceutical Limited's (HKG:1177) largest shareholder, CEO S. Y. Tse sees holdings value fall by 7.4% following recent drop
Inventiva SA reports €4.5 million revenue for first nine months of 2025
Reuters  ·  11-22
Inventiva SA reports €4.5 million revenue for first nine months of 2025
Sino Biopharmaceutical Stock Sheds 3.3% in Hong Kong
Dow Jones  ·  11-21
Sino Biopharmaceutical Stock Sheds 3.3% in Hong Kong
HKEX Announcement Highlights | XIAOMI-W Reports Record High Adjusted Net Profit of RMB11.311 Billion in Q3, Smartphone Shipments Grow YoY for 9 Consecutive Quarters
Stock News  ·  11-18
HKEX Announcement Highlights | XIAOMI-W Reports Record High Adjusted Net Profit of RMB11.311 Billion in Q3, Smartphone Shipments Grow YoY for 9 Consecutive Quarters

Introduction

Company Name.
SINO BIOPHARM
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Sino Biopharmaceutical Ltd is an investment holding company mainly engaged in the pharmaceutical business. The Company operates its business through three segments. The Modernised Chinese Medicines and Chemical Medicines segment is mainly engaged in the manufacture, sale and distribution of modernised Chinese medicine products and western medicine products. The Investment segment is mainly engaged in the long term investments business. The Others segment is mainly engaged in the related healthcare and hospital business.
Issue price:
--